A jury began deliberating Friday morning on whether Abbott Laboratories should pay GlaxoSmithKline hundreds of millions of dollars over allegations of unfair HIV drug pricing. Get the full story »
GlaxoSmithKline
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Glaxo lawyer: Abbott used HIV drug as weapon
Abbott Laboratories improperly hiked the price of one drug to help it preserve sales growth of one of its other HIV blockbusters, an attorney for GlaxoSmithKline told a jury. Get the full story »
Glaxo: Abbott has illegal monopoly in AIDS drugs
From Bloomberg News | GlaxoSmithKline Plc lawyers, in a trial seeking at least $1.5 billion in damages, told jurors that Abbott Laboratories had an illegal monopoly over HIV drugs. Get the full story>>
Feb. 28 at 1:19 p.m.
Comments Off
Filed under: FDA questions use of zinc in denture cream
The Food and Drug Administration suggested manufacturers consider taking zinc out of denture cream, after reports of neurological problems that might be associated with zinc poisoning.
Zinc is a mineral naturally present in some foods, available as a dietary supplement and added to certain products. Zinc has been added to denture cream to boost its adhesive properties. The FDA said in a Feb. 23 letter sent to denture-adhesive manufacturers that it’s received “numerous reports of adverse events related to the use of denture creams” consistent with zinc toxicity. Get the full story »
Glaxo to take $3.4B charge over Avandia marketing
GlaxoSmithKline will record a legal charge of 2.2 billion pounds ($3.4 billion) for the fourth quarter, effectively wiping out its profit, as it settles further claims related to Avandia and sales practices.
The charge equates to an after-tax cost of 1.8 billion pounds, more than the 1.45 billion the drugmaker had been expected to make in net income in the three months to December, according to Thomson Reuters consensus forecasts. Get the full story »
Former Glaxo lawyer charged with obstruction
A former lawyer for pharmaceutical giant GlaxoSmithKline Plc has been indicted on charges of lying and obstructing an investigation into the company’s promotion of an anti-depressant drug, the U.S. Justice Department said Tuesday.
The lawyer, Lauren Stevens, was indicted on four counts of making false statements, one count of obstruction of justice and one count of falsifying and concealing documents related to Glaxo’s promotion of the drug for weight loss, which had not been approved by the Food and Drug Administration. Get the full story »
Glaxo to pay $750M in Paxil settlement
Federal prosecutors in Massachusetts say British drug maker GlaxoSmithKline PLC will pay $750 million to settle allegations that its subsidiary manufactured and sold adulterated drugs, including the popular antidepressant Paxil.
U.S. Atty. Carmen Ortiz on Tuesday announced that GlaxoSmithKline has agreed to settle civil and criminal charges related to the subsidiary in Puerto Rico. Get the full story »
Avandia faces ban in Europe, severe limits in U.S.
European regulators said Thursday GlaxoSmithKline’s diabetes drug Avandia should be taken off the market but U.S. officials allowed it to stay, with major restrictions due to concerns about heart risks.
The differing rulings were an attempt to end a row over drug safety that has dogged the reputation of the medicine and its maker in recent years. Get the full story »
Abbott abandons plans to sell vaccines business
Drug and medical device firm Abbott Laboratories says it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies. Get the full story »
Flu vaccines on the way earlier than usual
Two flu vaccine makers said Friday that they had started shipping supplies for the U.S. market, one of the earliest starts to distributing seasonal influenza vaccine.
And U.S. officials said they were changing the labeling on a vaccine made by Australia’s CSL Ltd. because it appears to have caused a higher than usual rate of seizures in children. Get the full story »
Colgate sues to use “nurdle” on toothpaste
In a battle between two big toothpaste makers, Colgate-Palmolive Co. sued GlaxoSmithKline Plc Thursday, seeking a court order that its use of the “Triple Action” tagline and a three-stripe “nurdle” does not infringe the latter’s trademarks.
Colgate said it is concerned that Glaxo, which makes Aquafresh toothpaste, might sue over its use of the nurdle, given that the British company recently filed a trademark application that covers its design. Get the full story »
Panel votes to keep Avandia on market
U.S. health advisers said GlaxoSmithKline Plc’s diabetes drug Avandia should be allowed to stay on the market in some form, easing a threat of further litigation that could have followed a ban.
Twenty of the 33-member panel of outside experts convened by the Food and Drug Administration voted for various options that would allow Avandia to stay on the market despite concerns over associated heart risks. Get the full story »
July 13, 2010 at 12:22 p.m.
Comments Off
Filed under: Scientists debate fate of Avandia
FDA scientists debated how to interpret the outcome of a large clinical trial that GlaxoSmithKline PLC says backs the safety of its diabetes drug Avandia.
Avandia is currently being reviewed by a federal panel that is scheduled to vote Wednesday on whether it thinks Avandia should remain on the U.S. market. FDA Commissioner Margaret Hamburg opened the meeting Tuesday, telling advisers to “follow the science where ever it may lead and the rest will fall into place.” Get the full story »
Glaxo defends Avandia in hearings on drug’s safety
GlaxoSmithKline Plc insisted its diabetes pill Avandia was safe as U.S. advisers began a two-day meeting to consider whether the medicine is too dangerous to stay on the market.
The scientific experts assembled by the Food and Drug Administration are sorting through sharply conflicting data on whether Avandia causes heart attacks. Get the full story »
Abbott to sell Solvay’s flu-vaccine operation
From the Wall Street Journal | Abbott Labs has put the flu-vaccine business of Solvay SA up for sale. British pharmaceuticals giants GlaxoSmithKline and AstraZeneca are considered leading candidates to pick up the operation, expected to sell for around $617 million.
Abbott bought the drug business of Belgium’s Solvay in September.
